Safety and efficacy of Becaplermin gel in the treatment of diabetic foot ulcers

Blume, Peter; Bowlby, Melinda A.; Schmidt, Brian M.; Donegan, Ryan

doi:10.2147/cwcmr.s64905

Cited by 13 publications

(10 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The total healing score in each case was calculated by adding the scores of individual criteria, with lower scores indicating poorer wound healing. Healing status was graded as good (16)(17)(18)(19), fair (12)(13)(14)(15) and poor (8)(9)(10)(11).…”

Section: Papermentioning

confidence: 99%

See 1 more Smart Citation

Design of an apoptotic cell-mimetic wound dressing using phosphoserine–chitosan hydrogels

Lee,

Nabil,

Kwon

et al. 2023

Biomater. Sci.

View full text Add to dashboard Cite

show abstract

Section: Papermentioning

confidence: 99%

“…However, due to the complexity of the immune microenvironment in wounds, except for GM-CSF and PDGF, other cytokine treatments have remained FDA-unapproved. 13,14 Therefore, developing a new therapeutic approach capable of effectively modulating immune microenvironments for enhanced wound healing is of utmost importance.…”

Section: Introductionmentioning

confidence: 99%

Design of an apoptotic cell-mimetic wound dressing using phosphoserine–chitosan hydrogels

Lee,

Nabil,

Kwon

et al. 2023

Biomater. Sci.

View full text Add to dashboard Cite

show abstract

“…Thus, the evidence of becaplermin gel inducing cancer is still controversial. 66,67 For patient safety, the repeated and prolonged use of Regranex is not recommended by the FDA because of the associated increased risk of cancer. 68 In summary, the topical PDGF is effective in DM patient with neuropathic wound regardless of concomitant arterial occlusive disease and may decrease the probability of amputation.…”

Section: Platelet-derived Growth Factormentioning

confidence: 99%

Role of Topical Biological Therapies and Dressings in Healing Ischemic Wounds

Orrapin

Rekasem

2018

The International Journal of Lower Extremity Wounds

View full text Add to dashboard Cite

Ischemic wounds are the most severe expression of critical limb ischemia (CLI), and they have been defined clinically as an end stage of peripheral arterial disease. Urgent revascularization is a fundamental part for limb salvage in patients with CLI. However, the risk of revascularization should be weighed against the likelihood of success given a patient's life-threatening comorbidities. Once the condition of arterial insufficiency is revascularized, wound care is an important aspect to promote the wound healing process and infection control. MOIST concept for wound care is a modern systematic treatment for enhanced wound healing process. Currently, advanced biological therapies are emerging in ischemic wound therapies to restore the wound healing process and involve active biological agents to support the wound healing process. We studied and summarized the different types of available topical biological therapies and their mechanisms on the healing process including platelet-derived growth factor, epidermal growth factor, fibroblast growth factor, and vascular endothelial growth factor, platelet-rich plasma, and honey for local wound care of patient with CLI. Our review suggests that topical plateletderived growth factor, epidermal growth factor, platelet-rich plasma, and honey are available as well as considered in the ischemic wound healing process enhancement through the MOIST concept. In conclusion, biologic wound dressing or topical agent therapy may improve the wound healing process, increase limb salvage, is inexpensive, and provides potential safety with nontoxic low-risk therapy in patients with an ischemic wound. Thus, local wound care by biological dressing should be added in adjuvant treatment for ischemic wound patients. However, further randomized studies are needed to support efficacy and long-term outcomes of these biological dressing in patients with ischemic wound.

show abstract

“…Due to the complexity of chronic wounds, there are many limitations associated with current treatment modalities, including poor efficacy, incidence of wound recurrence or risk of tumour formation. Becaplermin gel, a growth factor therapy using a recombinant form of isoform PDGF-BB, aims to replace key degraded growth factors directly at the wound site; however, tumour formation has been reported following its use [ 15 , 18 , 19 ]. This highlights the importance of all the steps required to demonstrate the safety and efficacy of potential therapies.…”

Section: Introductionmentioning

confidence: 99%

Evidence for Natural Products as Alternative Wound-Healing Therapies

et al. 2023

View full text Add to dashboard Cite

Chronic, non-healing wounds represent a significant area of unmet medical need and are a growing problem for healthcare systems around the world. They affect the quality of life for patients and are an economic burden, being difficult and time consuming to treat. They are an escalating problem across the developed world due to the increasing incidence of diabetes and the higher prevalence of ageing populations. Effective treatment options are currently lacking, and in some cases chronic wounds can persist for years. Some traditional medicines are believed to contain bioactive small molecules that induce the healing of chronic wounds by reducing excessive inflammation, thereby allowing re-epithelisation to occur. Furthermore, many small molecules found in plants are known to have antibacterial properties and, although they lack the therapeutic selectivity of antibiotics, they are certainly capable of acting as topical antiseptics when applied to infected wounds. As these molecules act through mechanisms of action distinct from those of clinically used antibiotics, they are often active against antibiotic resistant bacteria. Although there are numerous studies highlighting the effects of naturally occurring small molecules in wound-healing assays in vitro, only evidence from well conducted clinical trials can allow these molecules or the remedies that contain them to progress to the clinic. With this in mind, we review wound-healing natural remedies that have entered clinical trials over a twenty-year period to the present. We examine the bioactive small molecules likely to be in involved and, where possible, their mechanisms of action.

show abstract

Safety and efficacy of Becaplermin gel in the treatment of diabetic foot ulcers

Cited by 13 publications

References 14 publications

Design of an apoptotic cell-mimetic wound dressing using phosphoserine–chitosan hydrogels

Design of an apoptotic cell-mimetic wound dressing using phosphoserine–chitosan hydrogels

Role of Topical Biological Therapies and Dressings in Healing Ischemic Wounds

Evidence for Natural Products as Alternative Wound-Healing Therapies

Contact Info

Product

Resources

About